Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China

BACKGROUND: Proton pump inhibitors (PPIs) have been recommended as standard of care for reflux esophagitis (RE). Vonoprazan (VPZ), a novel potassium-competitive acid blocker (P-CAB), has been approved in China after demonstrating clinical benefit in RE. However, there are not any published literatur...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenhua, Sun, Ruixiaotong, Sheng, Yanan, Qu, Shuli, Dong, Lu, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096411/
https://www.ncbi.nlm.nih.gov/pubmed/35571388
http://dx.doi.org/10.21037/atm-22-1722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096411/
https://www.ncbi.nlm.nih.gov/pubmed/35571388
http://dx.doi.org/10.21037/atm-22-1722

Ejemplares similares